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ABTRACT 
 
Purpose: KRAS mutation is a common canonical mutation in CRC, found at differing 
frequencies in all Consensus Molecular Subtypes (CMS). The independent 
immunobiological impacts of RAS mutation and CMS are unknown. Thus, we 
explored the immunobiological effects of KRAS mutation across the CMS spectrum. 
Experimental Design: Transcriptional analysis of immune genes/signatures was 
performed with RNA-seq using The Cancer Genome Atlas (TCGA) and the 
KFSYSCC data set. Multivariate analysis included KRAS status, CMS, tumour 
location, MSI status, and neoantigen load. Protein expression of STAT1, HLA-Class 
II, and CXCL10 was analysed by digital immunohistochemistry.   
Results: The Th1-centric co-ordinated immune response cluster (CIRC) was 
significantly, albeit modestly, reduced in KRAS mutant CRC in both data sets.  
Cytotoxic T cells, neutrophils and the interferon gamma pathway were suppressed in 
KRAS mutant samples.  The expression of STAT1 and CXCL10, were reduced at 
the mRNA and protein levels. In multivariate analysis KRAS mutation, CMS2 and 
CMS3 were independently predictive of reduced CIRC expression. Immune 
response was heterogeneous across KRAS mutant CRC: CMS2 KRAS mutant 
samples have the lowest CIRC expression, reduced expression of the interferon 
gamma pathway, STAT1 and CXCL10 and reduced infiltration of cytotoxic cells and 
neutrophils relative to CMS1 and CMS4 and to CMS2 KRAS wild type samples in the 
TCGA.  These trends held in the KFSYSCC data set.  
Conclusions: KRAS mutation is associated with suppressed Th1/cytotoxic immunity 
in CRC, the extent of the effect being modulated by CMS subtype. These results add 
a novel immunobiological dimension to the biological heterogeneity of CRC. 
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TRANSLATIONAL RELEVANCE 
 
Understanding how mutational and transcriptional differences mould the immune 
contexture in cancer is key to accurate immunobiological stratification. We analyse 
how KRAS mutation shapes the immune microenvironment of colorectal cancer 
(CRC) in the context of the Consensus Molecular Subtypes (CMS). We show that 
KRAS mutation is associated with modest suppression of Th1 cell and cytotoxic cell 
immunity independently of mismatch repair status, tumour location, neoantigen load 
and transcriptional subtype, but also show that the cumulative effect is dependent 
upon the CMS in which the mutation is found. Immunity in KRAS mutant CMS2 is 
more suppressed than CMS1 and CMS4 as well as in comparison with KRAS wild 
type CMS2. Our findings refine stratification factors for immunotherapy trial entry in 
CRC and suggest potential immunotherapeutic strategies to test in KRAS mutant 
patients. Variation in the immune status of RAS mutant CRC according to its 
transcriptional context might underlie part of the heterogeneity of response to 
molecularly stratified medicines. 
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INTRODUCTION 
 
Galon and colleagues first demonstrated the positive prognostic impact of tumour 
infiltrating lymphocytes (TILs) in colorectal cancer (CRC) (1). The strength of T 
helper type 1 (Th1) adaptive immunity was shown to be a strong prognostic factor.   
Th1 cells have an essential role in initiating and maintaining an effective CD8+ 
cytotoxic T cell response (2-4), in the recruitment of CD8+ cells to the tumour bed (5) 
and in directly mediating immunological tumour cell death (6).  Th1 cells recognize 
antigen in association with major histocompatibility complex class II (MHC-II) 
molecules.  They secrete the inflammatory cytokine interferon (IFN)-γ, which 
provokes class II up-regulation on tumour cells.  The majority of immunogenic neo-
epitopes are class II restricted (7).  Tumour cells evade cytotoxic immune responses 
by expressing the programmed death-ligand 1 (PD-L1) that activates the PD-1 
negative feedback pathway (8).  This checkpoint may be inhibited using an anti-PD-1 
antibody that blocks interactions between the PD-1 receptor and its ligand PD-L1.  
However, the strategy has only been efficacious in MSI-high CRC (9), i.e., those 
having a high neo-antigen burden that can stimulate immune infiltration (10).  Class 
II expression on cancer cells is clearly important in the efficacy of checkpoint 
blockage.  Indeed, cancer-cell MHC-II-negative melanoma patients have lower 
response rates, PFS and OS when treated with PD-1/PD-L1 blockade relative to 
class II-positive patients (11). Further, in vitro PD-L1 blockade enhances Th1-
mediated cytotoxicity only against cells that express high class II (12).  Hence, an 
effective immune response is critically dependent on neo-antigen presentation by 
MHC-II molecules.  
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The up-regulation of MHC-II molecules via the IFNγ pathway is dependent on the 
STAT1 and CIITA proteins: extracellular IFNγ induces and activates STAT1, which is 
the key transcriptional activator of CIITA.  CIITA is, in turn, the master transcriptional 
activator of MHC-II molecules.  STAT1-deficient cells show no induction of CIITA 
mRNA despite IFNγ stimulation (13) and STAT1-deficient cancer cells progress 
rapidly due to the evasion of adaptive immunity (14).  Class I-positive but class II-
negative mammary adenocarcinoma cells grew rapidly in immunocompetent mice, 
but were rejected when these cells were transfected with CIITA.  Rejection 
correlated with induction of class II expression and was mediated by both CD4+ and 
CD8+ cells. STAT1 deficiency also severely impairs the induction of CXCL10, 
another STAT1 target gene.  CXCL10 maintains the Th1 phenotype (15) and the 
decreased accumulation of Th1 cells in STAT1-deficient mice is related to reduced 
levels of CXCL10 (16).  
 
KRAS mutation is the commonest canonical gain of function mutation in CRC and 
earlier functional studies clearly demonstrated that mutant RAS reduces both STAT1 
and class II expression. Using three distinct cell line models (including Hct116, 
clones with deleted mutant KRAS, and intestinal epithelial cells with inducible mutant 
RAS), Klampfer and colleagues demonstrated that mutant RAS down-regulates both 
constitutive and IFNγ-inducible STAT1 mRNA and protein and reduces STAT1 
transcriptional activity and the expression of many IFNγ target genes including class 
II (17,18). Maudsley and co-workers showed that mutant KRAS resulted in loss of 
class II inducibility upon IFNγ treatment (without inhibiting class I expression), 
significantly reduced the ability of these cells to stimulate allogeneic T cells and 
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reduced the IFNγ secretion of the co-stimulated cells (19). They suggested that this 
RAS-mediated class II down-regulation interrupted an amplification loop whereby 
Th1 cells are stimulated to produce IFNγ that would otherwise stimulate further 
cancer cell class II expression. 
 
These isolated cell line experiments suggest a role for STAT1 and its target genes in 
RAS mutant CRC, but fail to replicate the complexities of the intact tumoural 
microenvironment.  Hence, guided by these pre-clinical studies, we asked whether 
RAS mutant CRC was associated with reduced expression of STAT1, CIITA, and 
CXCL10, as well as that of a number of associated signatures of immune reactivity, 
in human CRC tumour tissues. We have previously demonstrated using 
transcriptional analysis of bulk tumours that RAS mutant CRC is associated with 
lower expression of a Th1-centric immune metagene that we termed the Co-ordinate 
Immune Response Cluster (CIRC (20)). This metagene includes STAT1, CXCL10, 
nine separate class II genes, and the Th1 transcription factor T-bet (TBX21). We 
have also previously described a second immunological stratifier—the CRC 
“Consensus Molecular Subtypes” (CMS) (21). These subtypes include a 
“mesenchymal” group (CMS4) that is enriched for MSS tumours and yet is 
characterized by appreciable immune infiltration, intermediate between that of the 
MSI-enriched subtype (CMS1) and of the “canonical” (CMS2) and “metabolic” 
(CMS3) subtypes. RAS mutations occur in all of these CMS subtypes (albeit with 
differing proportions) and thus RAS mutations in CRC occur in different 
transcriptional contexts with heterogeneous biology. In particular, RAS mutations are 
present in both mismatch repair deficient and proficient cancers.  To determine 
whether these two stratifiers are independent, we dissected the various innate and 
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adaptive immune components of the CIRC in the context of CMS and KRAS 
mutation status using transcriptional analysis of two large independent datasets and 
digital immunohistochemistry analysis of compartment-specific protein expression. 
 
We demonstrate that CMS is more strongly associated with reduced anti-cancer 
immunity in CRC than RAS mutation, with both CMS2 and CMS3 being immune 
suppressed relative to CMS1 and CMS4. Nevertheless, we find that the modest RAS 
mutation association is significant and independent of expression subtype. The 
cumulative effect on immunity is dependent upon the CMS context of RAS mutation, 
with RAS mutant CMS2 being particularly immune suppressed.   
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MATERIALS AND METHODS 
 
Consensus Molecular Subtype (CMS) analysis 
Statistical analyses of TCGA and KFSYSCC expression data were performed in R 
(http://www-r.project.org).  To summarize the expression of a gene set [i.e., CIRC, 
immune subpopulations (22), and Hallmark gene sets (23)], we condensed the 
expression of the multiple genes in the set into a single gene set enrichment value 
using Gene Set Variation Analysis (GSVA) (24). Two-tailed non-parametric Wilcoxon 
rank sum tests, two-tailed t tests, two-tailed Fisher’s tests, and one-tailed F tests 
were applied, as indicated.  Relative enrichments or expression between two 
populations is summarized by the Hodges-Lehmann estimator of the difference 
between those populations—e.g., the median of all pairwise differences between 
CIRC enrichment in a KRAS MT sample and a KRAS WT sample. 95% confidence 
intervals in this estimator were calculated using the method of Bauer (25).  
Multivariate analyses were performed using the forestmodel R package, with 
linear model CIRC ~ KRAS + CMS + site + status + neoantigens and 
where CIRC is the gene set enrichment for the immune signature, site indicates 
tumour location as left, right, or rectum, KRAS indicates mutation status WT or 
MT, CMS indicates subtype, status indicates MSI or MSS, and neoantigens is a 
continuous value indicating the (log-transformed) number of neoantigens. To assess 
potential synergy between the main effects corresponding to CMS subtype (CMS) 
and KRAS mutation status (KRAS), we used ANOVA to compare linear models with 
and without the interaction effect (CMS:KRAS), i.e., CIRC ~ CMS + KRAS versus 
CIRC ~ CMS + KRAS + CMS:KRAS. Samples that did not correspond to one of the 
four CMS groups (i.e., “unlabelled”) were excluded from any analysis that include 
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CMS. Expression data sets, as well as clinical annotations, CMS labels, neoantigen 
predictions (obtained from The Cancer Immune Atlas (26)), and gene set definitions, 
are available on the Synapse data commons platform [(27) and 
https://www.synapse.org] under Synapse ID syn8533552.  Source code to perform 
all genomic analyses and to generate the respective figures is available at 
https://github.com/Sage-Bionetworks/crc-cms-kras.  Additional detail is provided in 
Supplemental Methods. 
 
Immunohistochemical analysis 
Samples for IHC from patients undergoing resection of primary CRC were obtained 
from the completed CRUK Stratified Medicine Programme One pilot study and CRC 
patients from the Queen Elizabeth Hospital, Birmingham.  Samples were collected 
under ethical approval HBRC 14-205 (Sponsor: University of Birmingham). All 
patients had provided informed written consent for the use of their tissue, and 
studies were conducted in accordance with the Declaration of Helsinki.  The cohort 
comprised 28 RAS G12D/G13D mutants (24.3%), 38 RAS non-G12D/G13D mutants 
(33.0%), and 49 RAS wild types (42.65) for a total of 115.   Suitable formalin-fixed, 
paraffin-embedded (FFPE) blocks were retrieved and processed at the HBRC 
biobank, University of Birmingham. Microsatellite status was assessed by extracting 
total DNA from FFPE tumour scrolls by fragment analysis (Supplemental Methods).  
7 tumours (6.09%) were MSI-H, of which 3 were RAS mutant.    
IHC was performed using a Leica Bondmax autostainer.  For STAT1 an antibody 
that had undergone robust validation was selected (Cell Signalling Technology 
(CST) clone D1K9Y). For Class II HLA (Abcam clone CR3/43) and CXCL10 (Novus 
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Biologicals clone 6D4), in-house validation was performed as described in 
Supplemental Methods. 
 
Staining conditions and concentrations were iteratively optimised in conjunction with 
a histopathologist (PT):  STAT1: 1:500, 20 minute incubation, Class II HLA: 1:100, 
20 minutes, CXCL10: 1:50, 20 minutes. Slides were scanned at 40x magnification 
using a Leica SCN400 slide scanner and digitally analysed using Definiens Tissue 
Studio software.  Analysis algorithms were created and optimised for each marker.  
Regions of interest (ROIs) were created in the tumour regions of each slide.  All 
tumours were digitally segmented into tumour epithelium and stroma regions using 
trained segmentation algorithms (Supp Figs 1 A and B).  Depending on the marker, 
staining was quantified on a per cell basis or on an area basis (Supp Fig 1 C and 
D).  Percentages of cells or pixels with high, medium, low or no immunoreactivity 
were quantified in each region.  This produced either histological scores for cell-
based scoring, or percental scores for pixel-based scoring, which are functions of the 
number and intensity of immunoreactive cells or pixels in the scanned specimens 
respectively (1 × (% cells/pixels with low staining) + 2 × (% cells/pixels with medium 
staining) + 3 × (% cells/pixels with high staining) = score out of 300).  Thresholds for 
negative/low, low/medium and medium/high were set for each antibody in 
conjunction with a pathologist to maximise the dynamic range of results between 
samples and to reduce false positive results. Haematoxylin thresholds (the staining 
intensities at which haematoxylin was recognised) were set individually and differed 
for each antibody due to differences in DAB staining.  Haematoxylin thresholds were 
set to ensure accurate identification of individual cells. After analysis, segmentation 
was manually validated for each slide.   
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IHC results were analysed using Excel (Microsoft Corp) and Minitab (Minitab Inc).  
The normality of the distribution of Histological scores in each group (RAS mutant or 
RAS wildtype) was determined by performing the Anderson-Darling test.  All data 
were non-parametrically distributed.  Therefore, for one by one comparisons, Mann 
Whitney U tests were performed for significance testing.  In addition, for STAT1 and 
CXCL10, staining for each case was grouped into low and high using H-score 
thresholds of both 100 and 200.  For Class II HLA, cases were grouped into negative 
(0-5% staining), low (5-50% staining) and high (>50% staining) as described by 
Lovig et al (28) (Supp Fig 2 F-H).  Chi-squared tests were performed to investigate 
significance between the RAS mutant and wild type groups. A p-value <0.05 was 
considered significant. 
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RESULTS 
 
Immune subpopulations are suppressed in KRAS MT CRC 
In our previous work we demonstrated that RAS mutant CRC had lower expression 
of the CIRC, a metagene that integrates 28 genes involved in innate and adaptive 
immunity (20). The CIRC was defined using 195 microarray CRC samples, of which 
190 have also been subjected to RNA sequencing as part of an extended TCGA 
study.  We analyzed this full data set (n=344) to validate our original findings on the 
orthogonal RNA-seq platform: consistent with those previous results, the analysis 
showed a significant reduction in the expression of the CIRC metagene in KRAS MT 
relative to WT (Supp Fig 3A; two-tailed Wilcoxon rank sum p = 2.4 x 10-3).  We 
additionally validated these results in the independent KFSYSCC (29) data set 
(n=290) of fresh-frozen CRC samples (Supp Fig 3B; two-tailed Wilcoxon rank sum p 
= 4.4 x 10-3).   
 
The CIRC signature was previously defined by performing an unsupervised 
hierarchical clustering of TCGA patients based on 61 highly-curated, immune 
response-related genes.  The genes comprising the signature were selected based 
on their strong coordinated regulation across patient subgroups (20). The CIRC is 
enriched for Th1-associated genes, as well as genes encoding chemokines, 
adhesion molecules, MHC class II molecules, and immune checkpoints.  Therefore, 
to dissect the specific immune subpopulations differentially recruited to KRAS MT 
tumours, we examined the effect of KRAS mutation on expression of each of seven 
immune cell types [neutrophils, and immature dendritic (iDC), B, T, Th1, Th2, and 
cytotoxic cells (22)]. Despite having few genes in common (Supp Fig 4), all immune 
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subpopulations except Th2 cells were highly correlated with the CIRC in both data 
sets (Pearson correlation r ≥ 0.42; p ≤ 6.4 x 10-14; Supp Fig 5).  Cytotoxic (r ≥ 0.85; p 
≤ 4.3 x 10-82), T (r ≥ 0.73; p ≤ 2.7 x 10-50), and, as expected, Th1 (r ≥ 0.71; p ≤ 3.2 x 
10-45) cells were most highly correlated with the CIRC in both data sets. KRAS 
mutation is associated with reduced cytotoxic cell (Fig 1A; TCGA: two-tailed 
Wilcoxon rank sum p = 0.04; KFSYSCC: p = 0.02) and neutrophil (TCGA: p = 9.7 x 
10-3; KFSYSCC: p = 5.3 x 10-3) infiltration. Th1 cells themselves consistently trend 
towards reduced infiltration in KRAS MT CRC (TCGA: p = 0.09; KFSYSCC: p = 
0.13). To further characterize biological differences between KRAS MT and WT CRC 
we compared the differences in expression of all 50 Hallmark gene sets (23).  This 
revealed down-regulation of multiple immune-related pathways within KRAS MT 
tumours across both data sets (Fig 1B).  In particular, we observed suppression of 
the IFNγ pathway in KRAS MT CRC in both data sets.  
 
STAT1 and CXCL10 are downregulated in KRAS MT CRC 
Given the disruption of the IFNγ pathway in KRAS MT CRC, we hypothesized that 
downstream genes would also be affected in these tumours.  To test this, we 
examined the expression of the key IFNγ response gene, STAT1, at the mRNA level 
and at the protein level using digital immunohistochemistry (IHC; Supp Figs 2 A-E).  
We found that STAT1 mRNA expression was down-regulated in KRAS MT CRC in 
both data sets (Supp Fig 6). By performing IHC and then digitally segmenting 
tumours into epithelium, stromal, and background regions (Supp Figs 1 A and B), 
we found that the STAT1 protein was also down-regulated in the epithelial 
compartment across a series of whole mount sections taken from 115 patients with 
primary CRC samples (RAS G12D/G13D MT n = 28, RAS non-G12D/G13D MT n = 
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38, RAS WT n = 49): STAT1 expression was reduced by RAS mutation whether 
samples were analysed by H-scores (p = 0.016) or according to percentage of 
positive staining for STAT1 (χ2 p = 0.033; Table 1).  
 
We next asked whether STAT1 target molecules, CXCL10 and CIITA, were also 
dysregulated in KRAS MT tumours.  We found that CXCL10 was strongly down-
regulated in both data sets (Supp Fig 6). This down-regulation was confirmed at the 
protein level, with significantly more MT samples having H-scores <100 (χ2 p = 0.04) 
and significantly more WT samples having H-scores >200 (χ2 p = 0.03; Table 1).  
We also found that CIITA was down-regulated in KRAS MT samples in the TCGA 
data set (Supp Fig 6). Though there was no such evidence for dysregulation of the 
mRNA in the KFSYSCC data set (Supp Fig 6), CIITA expression was generally low 
in this data set (median CIITA expression below the fifth percentile). At the protein 
level, around 50% of both RAS MT and RAS WT CRC samples were completely 
negative for class II expression by IHC and only 6.4% RAS MT tumours had >50% 
class II positive cells (Supp Figs 1 C-D and 2 F-H; Table 1). When class II protein 
expression was analysed in the cancer samples that had detectable expression of 
class II [i.e., excluding the class II negative cases in which transcriptional silencing of 
CIITA would prevent IFNγ inducibility via STAT1 (30,31)], we found that RAS 
mutation was associated with reduced class II expression on the cancer cells (RAS 
MT class II expressing CRC median epithelial class II H-score = 136.14, RAS WT 
median = 168.33, Mann-Whitney U p = 0.01) with no differences in stromal class II 
expression (RAS MT CRC stromal median = 146.96, RAS WT median = 141.56, 
Mann-Whitney U p = 0.16).  
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Reduced immune infiltration is independently associated with KRAS mutation 
and CMS subtype  
Immune response in CRC has been reported to be suppressed in CMS2 (21).  
Hence, we hypothesized that the CIRC and other measures of immunity would be 
lowest in KRAS MT CMS2 tumours. We first confirmed that the CIRC was strongly 
suppressed in CMS2 relative to CMS1 and CMS4 in both the TCGA (Supp Fig 7A; 
CMS2 versus CMS1: two-tailed Wilcoxon rank sum p = 1.2 x 10-18; CMS2 versus 
CMS4: p = 5.5 x 10-15) and KFSYSCC (Supp Fig 7B; CMS2 versus CMS1: p = 1.1 x 
10-4; CMS2 versus CMS4: p = 9.0 x 10-8) data sets.  As expected, CMS2 KRAS MT 
samples had the lowest CIRC expression amongst all CMS subtype x genotype 
combinations in the TCGA data set (Fig 2A).  These results were independently 
validated in the KFSYSCC data set (Fig 2B), though the consistent trends in relation 
to CMS3 did not always reach significance.  To determine whether KRAS mutation 
status and CMS classification are significantly and independently associated with 
immune infiltration, we performed a multivariate analysis of CIRC expression that 
included as parameters KRAS mutation status, CMS classification, primary tumour 
location, and, in the TCGA data set where they were available, MSI status and 
neoantigen load.  The analysis showed that KRAS MT and CMS2 (relative to CMS1 
and CMS4) were independently predictive of reduced CIRC expression in the TCGA 
(Fig 3A) and KFSYSCC (Fig 3B) data sets.  We next assessed whether KRAS 
mutation might have a CMS subtype-dependent effect. However, there was no 
evidence for a KRAS x CMS interaction in either data set (TCGA: F test p = 0.15; 
KFSYSCC: p = 0.67).  Finally, to delineate potential differential infiltration of specific 
subpopulations associated with KRAS MT CMS2 tumours, we examined the immune 
subpopulations most strongly associated with KRAS status (Fig 1A) in the additional 
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context of molecular subtype.  We found that KRAS MT CMS2 tumours had reduced 
infiltration of cytotoxic cells relative to all other patient groups in the TCGA data set 
(Fig 4A), with a similar trend in the KFSYSCC data set (Fig 4B).  KRAS MT CMS2 
tumours also showed reduced infiltration of neutrophils and Th1 cells in both data 
sets relative to CMS1 and CMS4 patients, but not necessarily to CMS2 WT or CMS3 
(MT or WT) patients. 
 
Taken together, our results indicate that there is considerable heterogeneity within 
CMS subtypes, even when controlling for MSI status, and that this may be further 
dissected using KRAS mutation status.  Though the data could not unambiguously 
resolve whether KRAS mutation has an effect specific to CMS2, the two factors are 
independently significant, i.e., the level of immune infiltration and its characterization 
across immune cell subpopulations cannot be inferred without knowledge of both 
factors.  The cumulative effect is such that CMS2 KRAS MT samples have reduced 
immune infiltration (of cytotoxic cells, neutrophils, and Th1 cells, as well as 
measured by the CIRC) relative to CMS1 or CMS4 samples harboring either MT or 
WT KRAS. 
 
IFNγ pathway suppression is associated with both KRAS mutation and CMS 
subtype 
To determine whether immune pathways down-regulated in KRAS MT tumours (Fig 
1B) were additionally suppressed in CMS2 CRC, we evaluated the expression of 
these signatures in the context of KRAS mutation status and molecular classification.  
In the TCGA data set, we found that KRAS MT CMS2 tumours exhibited reduced 
expression of all examined immune signatures (IFNγ, inflammatory response, 
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IL6/JAK/STAT3 signaling, complement, and IFNα) relative to all patient groups 
(though the trend did not reach significance in relation to KRAS WT CMS2 when 
examining the IFNα pathway; Fig 4C).  These trends held in the KFSYSCC data set 
(Fig 4D).  In particular, KRAS MT CMS2 tumours showed significantly reduced 
expression of the IFNγ pathway relative to all other patient groups in both data sets, 
except relative to KRAS WT CMS2 in the KFSYSCC data set, which nevertheless 
exhibited the same trend (p = 0.05). 
 
Finally, we examined the downstream target of the IFNγ pathway, STAT1, as well as 
its downstream targets, CXCL10 and CIITA, to determine whether the previously-
observed association between the reduced expression of these three genes and 
KRAS mutation was independent of molecular subtype. First, we observed that, 
within CMS2, KRAS MT samples had lower expression of each of the genes relative 
to WT samples in both the TCGA (p < 0.02) and KFSYSCC (p < 5.8 x 10-3) data 
sets, with the exception of CIITA in the KFSYSCC data set, as expected from its low 
expression in this data set (Supp Fig 8).   Second, we performed multivariate 
analyses for all three genes in both data sets, excluding CIITA in the KFSYSCC data 
set, which generally indicated that both KRAS mutation and CMS2 (relative to CMS1 
and CMS4) were significantly and independently associated with reduced expression 
of the three genes.  Specifically, KRAS mutation was significantly (p < 1.1 x 10-2) or 
marginally (p = 0.05 for STAT1 in the TCGA data set) associated with reduced gene 
expression, while CMS2 was associated with reduced gene expression relative to 
CMS1 (p < 3.1 x 10-3) and to CMS4 (p < 1.2 x 10-3, except for STAT1 in the 
KFSYSCC data set, where p = 0.17).  
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DISCUSSION 
 
We have previously shown that KRAS mutation is associated with reduced 
expression of the CIRC metagene, which summarizes 28 genes associated with 
innate and adaptive immunity.  Here, we extend those earlier findings to: (1) explicitly 
characterize the nature of the suppressed immune infiltration, showing that KRAS 
MT tumours have reduced infiltration of cytotoxic cells and neutrophils (Fig 1A); (2) 
demonstrate that the IFNγ pathway is suppressed in KRAS MT tumours (Fig 1B); (3) 
demonstrate that KRAS mutation is associated with down-regulation of  STAT1 and 
CXCL10 at the mRNA (Supp Fig 6) and protein (Table 1) levels; (4) show that 
KRAS MT-associated immunosuppression is independent of CMS classification (Fig 
3 and Supp Fig 8); and (5) show that KRAS MT CMS2 CRC is significantly 
immunosuppressed relative to (KRAS MT or WT) CMS1 and CMS4 cancers and, 
based on several signatures in at least one of the two data sets, relative to KRAS 
WT CMS2 CRC as well (Figs 2 and 4).   
 
The KRAS MT-associated down-regulation of the IFNγ pathway and reduced 
infiltration of cytotoxic T cells (i.e., those with properties common to CD8+ T, Tγδ, 
and natural killer cells) and neutrophils indicate that the immunosuppressive impact 
of KRAS mutation that we previously observed is robust, if modest.  Recent data 
demonstrate the interconnectedness of CD8+ T cells and neutrophils with the 
IFNγ pathway (32):  addition of neutrophils to CD8+ T cells (activated via sub-optimal 
concentrations of anti-CD3 and anti-CD28 antibodies) led to increased IFNγ release 
and T cell proliferation. In turn, activated CD8+ cells enhanced neutrophil viability. 
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Furthermore, activated neutrophils co-localize with immature DCs, leading to their 
maturation (33).  The resulting DCs drive T cell proliferation and Th1 skewing.  
 
Pre-clinically RAS mutation has been shown to reduce the levels of STAT1 (17,18). 
Consistent with these findings, we demonstrated that RAS MT cancers are 
associated with significantly lower STAT1 within the context of the tumour 
microenvironment.  The pre-clinical data also showed that RAS mutation reduced 
STAT1-dependent transcriptional activity (17); indeed, we detected reduced 
expression of the STAT1 target CXCL10 at the RNA and protein levels in KRAS MT 
relative to WT samples.   KRAS mutation may additionally down-regulate CXCL10 
via its activation of MEK-ERK signalling, which we observed in both data sets using 
a previously published (34) five-gene MEK signature (data not shown). We observed 
that KRAS MT reduced expression of a second STAT1 target, CIITA, in the TCGA 
data set.  No such trend was detected in the KFSYSCC data set.  However, CIITA 
expression was suppressed in this data set, which would likely mask any KRAS MT-
mediated STAT1 impact. Transcriptional repression of CIITA is seen in a proportion 
of CRC samples (30) as is the complete failure of IFNγ to induce class II expression 
in half of primary CRC cells (31). Both of these effects are RAS-independent. To 
control for CIITA silencing (and thus lack of class II inducibilty), we analysed the 50% 
of CRC samples that detectably expressed class II molecules (and in which CIITA 
must be transcribed and hence under the influence of STAT1).  In these samples, we 
demonstrated that RAS MT cancers had significantly lower expression of class II 
surface makers compared with RAS WT cases. Significantly, we demonstrated that 
both CMS classification and KRAS mutation status are independently and 
significantly associated with dysregulation of STAT1, CXCL10, and CIITA.  The 
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CMS-associated effect presumably reflects previously-reported reduced IFNγ 
signalling in CMS2 tumours (21), which leads to correspondingly reduced 
transcription of STAT1 target genes (17).  Our findings and the cited literature are 
consistent with a cell autonomous role for KRAS in modulating STAT1 and its 
downstream targets CXCL10 and CIITA.  Nevertheless, we cannot formally exclude 
the possibility that this KRAS effect is attributable, in whole or in part, to the reduced 
immune infiltration of CMS2 CRC with corresponding reduced environmental IFNγ. 
However these two factors are clearly intimately related. 
 
Suppression of the CIRC was greatest in KRAS MT CMS2 samples. There may be a 
straightforward explanation for this phenomenon. CMS2 is the most Th1 immune 
suppressed of the molecular sub-types with the lowest level of IFNγ signalling and 
thus lower levels of STAT1 and STAT1 target gene transcription.  KRAS mutation 
shifts the IFNg/STAT1 dose response curve (17), such that for any level of IFNγ 
there is less STAT1 transcription in a KRAS mutated context. This effect is likely to 
be most biologically relevant where IFNγ levels are already limiting. The cumulative 
impact of low IFNγ (CMS2) and blunting of the IFNγ response (via mutant KRAS) 
may result in a level of STAT1-dependent promoter transcription that is insufficient to 
support robust and consistent expression of the critical downstream molecules. We 
considered the alternative explanation - that the effect of KRAS mutation in CMS2 
was due to it impacting the particular biology of CMS2. This subtype is characterised 
by high levels of Wnt and Myc signalling (21). Activation of WNT/β-catenin signalling 
in melanoma reduces CD8+ T and IFNγ-producing CD4+ cells, findings which have 
been generalized across other cancer types including CRC (35), while MYC up-
regulation has been associated with reduced CD4+ T cell tumoural accumulation 
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(36). In vitro, mutant RAS significantly enhances WNT/β-catenin signalling in a 
mutant APC background and enhances downstream MYC transcription (37).  Thus 
we investigated whether KRAS mutation was deepening the Wnt and Myc drive in 
CMS2, and thus deepening immunosuppression via this mechanism. We found no 
robust, consistent evidence that KRAS mutation dysregulated the expression of the 
WNT or MYC signatures within the context of CMS2 (p > 0.07 for comparisons of 
KRAS MT CMS2 vs KRAS WT CMS2 for WNT/β-catenin and MYC target gene sets).  
 
 
As is the case for the majority of transcriptional and immunohistochemical analyses 
in CRC, our analysis was performed using primary resection samples. It is important 
to stress that the strength of Th1 immunity and class II expression in primary tissue 
are highly prognostic factors and are predictive of the presence of both synchronous 
metastatic disease and the development of subsequent metastases (38). Thus, 
understanding the independent impacts on the strength of Th1 immunity in primary 
tissue is of value in its own right.  These results pose important questions for the 
larger body of immunotherapy trials that are instead directed at established 
metastatic or, in an adjuvant context, micrometastatic disease. Longitudinal 
expression studies following the evolution of disease progression should be 
undertaken to ascertain the concordance of CMS classification between primary and 
metastatic disease.  However, existing data already suggest that immune cell 
densities (CD8+, dendritic, and NK cells) are highly correlated between primary and 
metastatic CRC and between separate metastatic sites (39). Though it has been 
suggested that there is significant intra-tumoural heterogeneity of CMS, this analysis 
used separately macro-dissected tissue from the center of the tumour and from the 
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invasive front rather than bulk tumour (40). As was pointed out in the accompanying 
editorial, biopsy from the invasive margin will result in a large admixture of stromal 
cells not found in the center of the tumour thus giving a CMS4-like signature and 
artificially introducing heterogeneity through selective sampling (41). Regardless of 
whether CMS or some other molecular subtypes prove to be pertinent to metastatic 
CRC, our results suggest that KRAS mutation is likely to modulate immune response 
within these subtypes:  these data provide proof of principle that the immune status 
of RAS mutant CRC is not homogenous across all CRC and that RAS mutation 
influences the immunobiology of molecularly-defined CRC subtypes.  
 
In summary, our results add a novel immunological dimension to the growing 
appreciation of the biological heterogeneity of tumours harbouring canonical 
mutations in CRC. The immunobiological status of RAS mutant CRC varies 
according to transcriptional context and the immunobiological status of CMS2 is 
dependent on RAS status. KRAS MT CMS2 appears to be a particularly immune-
neglected group that will need therapy to initially activate a microenvironmental 
immune response if checkpoint blockade is considered in a combinatorial approach. 
RAS mutation itself may be a useful immunological target in this group. Adoptive T 
cell transfer of RAS MT-specific T cells has recently been shown to have therapeutic 
efficacy in CRC (42) and the use of T cells transduced with T-cell receptors 
recognising RAS MT epitopes is also a potential therapy option (43).  Our 
demonstration that a canonical mutation can be associated with widely differing 
expression of immune-related genes based on its transcriptional subtype may 
underlie some of the heterogeneity of responses seen with targeted therapies, 
although it is important to qualify this by acknowledging that our understanding of the 
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transcriptional biology of metastatic disease is limited. In animal models, the activity 
of BRAF inhibitors is dependent on Th1 cell-mediated provision of CD40L and IFNγ 
(44). Similarly, the therapeutic effect of inactivation of oncogenic MYC is dependent 
upon CD4+ cells (45). This suggests that the use of individual mutations as 
predictive biomarkers in CRC may be insufficient to predict the efficacy of targeted 
therapies without knowledge of the associated CMS subtype and its immune 
contexture.  This hypothesis should be readily testable in the clinic. 
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TABLES 
Table 1 
 
Epithelium Stroma 
RAS MT RAS WT p value RAS MT RAS WT p value 
STAT1 
Median H Score 180 238 0.016 88 122 0.086 
% H score <100 32.2 10.5 0.014 54.2 47.4 0.508 
% H score >200 40.7 60.5 0.056 13.6 23.7 0.200 
CXCL10 
Median H Score 93.5 108 0.080 24 24 0.858 
% H score <100 58.1 38.3 0.041 85.5 85.1 0.956 
% H score >200 8 23.4 0.025 4.8 2.1 0.558 
Class II HLA 
Median Percental 
Score 125.2 136.8 0.260 143.9 135.8 0.051 
% Negative (0-5%) 50.8 51.2 
0.590 
11.3 20.9 
0.300 % Positive (5-50%) 42.9 37.2 87.1 79.1 
% Strong (>50%) 6.4 11.6 1.6 0 
  
Table 1: Immunohistochemistry analysis.  Median Histological scores or 
Percental scores in epithelial and stromal regions.  STAT1 and PD-L1 reactivity are 
represented by histological scores.  Class II HLA reactivity is represented by 
percental scores.  For median H and percental scores, p-values are derived with 
Mann Whitney U test.  For all other comparisons, p-values are derived with χ2 test. 
 
  
30 
 
FIGURE LEGENDS 
 
Fig 1:  KRAS mutation is associated with reduced immune infiltration and 
downregulation of immune pathways.  (A) Volcano plot showing enrichment (x 
axis) of immune cell subpopulations in KRAS MT relative to KRAS WT tumours, with 
associated p-values (y axis) across TCGA (red) and KFSYSCC (blue) data sets.  
Relative enrichment is the Hodges-Lehmann estimator of the difference between the 
KRAS MT and KRAS WT populations—i.e., the median of all pairwise differences 
between CIRC enrichment in a KRAS MT sample and a KRAS WT sample. (B) 
Volcano plot as in (A), but showing effect of KRAS mutation on Hallmark gene sets.  
The subset of the full set of 50 Hallmark gene sets with p < 0.1 are labeled.   
Fig 2: CIRC expression is reduced in CMS2 KRAS mutant tumours.  Expression 
of CIRC versus CMS subtype and KRAS mutation status in (A) TCGA (n=316) or (B) 
KFSYSCC (n=258) data sets.  n.s.: not significant; *: p < 0.05; **: p < 0.01; ***: p < 
0.001; ****: p < 0.0001; MT: mutation; WT: wild type. 
Fig 3: CMS subtype and KRAS mutation are independently predictive of CIRC 
expression. Multivariate analysis performed across (A) TCGA (n=310) or (B) 
KFSYSCC (n=258) data sets.   
Fig 4:  KRAS MT CMS2 tumours are associated with reduced immune 
infiltration and downregulation of immune pathways.  Enrichment score (y axis) 
of immune populations (x axis) of indicated KRAS x CMS subgroup relative to KRAS 
MT CM2 subgroup in (A) TCGA and (B) KFSYSCC data sets.  Relative enrichment is 
the Hodges-Lehmann estimator of the difference the indicated subgroup and KRAS 
WT CMS2 subgroups.  Error bars represent 95% confidence intervals in estimator 
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calculated using the method of Bauer (25).  Enrichment relative to KRAS MT CMS2 
subgroup of Hallmark immune pathways in (C) TCGA and (D) KFSYSCC data sets.   
 
 
 
 
 
